返回 Agendas
Session 3C: Clinical Track: Antiviral
Session Chair(s)
Arthur A. Levin, PHD
Distinguished Scientist
Avidity Biosciences, United States
The first application of an oligonucleotide agent in 1978 was to inhibit viral replication (Zamecnik, and Stephens, 1978 PNAS) and the first approved oligonucleotide drug. Fomivirsen was an antiviral. Presently, there are multiple oligonucleotide therapeutics in clinical trials including siRNA, miRNA, and antisense modalities. In this session several new approaches to antiviral activities will be presented. A novel Nucleic Acid Polymer system for the treatment of HBV will be discussed. An siRNA approach that uses a lipid nanoparticle to deliver multiple siRNAs and a conjugated anti-miR will also be presented. Each brings to the meeting a unique prospective for the development of oligonucleotide therapeutics.
Speaker(s)
Clinical Experience with Nucleic Acid Polymers in the Treatment of Chronic HBV and HBV / HDV Co-infection
Andrew Vaillant, PHD
Replicor, Canada
Chief Scientific Officer and VP, Operations
TKM-HBV, a Lipid Nanoparticle RNA Interference Treatment for Chronic Hepatitis B
Amy Lee
Tekmira Pharmaceutical Corporation, Canada
Research Director
miR-122 – Potential as a Therapeutic Target for Treating Chronic Hepatitis C Infection
Paul C. Grint, MD
Regulus Therapeutics, United States
Chief Medical Officer
Panel Discussion
All Session Speakers, United States